Please assess the completion status of the following clinical trial:

Trial Title: Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* male \& female subjects greater than or equal to 18 years of age with newly diagnosed or relapsing mild to moderate ulcerative colitis~* general medical assessment satisfactory and no clinically significant and relevant abnormalities~Exclusion Criteria:~* severe ulcerative colitis~* subject in relapse for \> 6 weeks~* use of systemic or rectal steroids within last 4 weeks prior to baseline~* subjects with proctitis, previous colonic surgery, Crohn's disease, bleeding disorders, active ulcer disease~* subjects hypersensitive to salicylates/aspirin~* subjects with moderate or severe renal impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).